Creative Biolabs is an undisputed global leader in the IVD (in vitro diagnostic) industry and provides IVD antibody development services for various biomarkers of a wide variety of diseases. Especially, Creative Biolabs offers high-quality antibody development services for diagnostic applications targeting UH-RA.21 as a potential biomarker for rheumatoid arthritis.

Early Diagnosis of Rheumatoid Arthritis

Related progress in biomarker discovery for RA diagnostics leads to the presence of previously identified autoantibodies to novel Hasselt University (UH) peptides in early and seronegative RA. UH-RA.1, UH-RA.9, UH-RA.14, and UH-RA.21 have been identified as four new biomarkers that can help in the early diagnosis of RA, specifically in patients who test negative for currently recognized antibodies. The new biomarkers play important role in a plan to early diagnosis of RA to determine the feasibility of widespread use.

UH-RA.21 marker- Creative Biolabs

Novel UH-RA.21 Biomarker for Rheumatoid Arthritis

Recently, autoantibodies against novel UH-RA peptide UH-RA.21 were identified as a candidate biomarker for patients with RA who are seronegative for the current diagnostic markers rheumatoid factor and anticitrullinated protein antibodies. In addition, assigning the isotype profile might provide valuable information on effector functions of the antibodies. As UHRA.21 constitutes a mimotope, the immunohistochemical analysis with anti-UH-RA.21 antibodies could provide some insight into the in vivo antigenic target corresponding to UH-RA.21. Anti UH-RA.21 antibodies were immuno-affinity purified from an antibody-positive RA plasma sample by the use of UH-RA.21 peptide-coated beads.

IVD Antibody Development Services for UH-RA.21 Marker

Antibodies are core elements for antibody-based immunoassays for detecting and quantifying antigens of interest in all kinds of samples such as serum, urine, tissue preparations, and so on. IVD antibodies are extensively used for disease screening, prognosis, and therapeutic monitoring. With our versatile IVD platform, Creative Biolabs is proud to develop novel UH-RA.21-specific antibody from scratch to commercial IVD kit (we can also start with provided antibody candidates).

Creative Biolabs is well-positioned to deliver a focused product to the research market representing the highest value targets for the diagnosis and prognosis of RA. Creative Biolabs has extensive expertise and experience to meet customized requirements of your research and project. We have extensive experience in generating IVD antibodies, please do not hesitate to contact us for more details.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.